The crux of the controversy lies in the fragmented evidence base. Randomized controlled trials (RCTs), often considered the gold standard in evaluating therapeutic interventions, tend to exclude infants below 36 weeks’ gestation to minimize confounding variables attributable to prematurity. Consequently, the existing RCT evidence does not unequivocally support administering TH to infants at exactly 35 weeks, which introduces ambiguity into clinical guidelines. Observational studies, however, have documented varying degrees of benefit and safety, finding some suggestive signals favoring thoughtful application of TH in these earlier gestations. This dissonance between rigorous trial data and real-world clinical observations has challenged practitioners grappling with the ethical imperative to balance benefit against harm.

Variability in clinical practice has proliferated in response to this knowledge gap. Some neonatal intensive care units (NICUs) extend TH eligibility to 35-week neonates, interpreting observational findings as rationale for early intervention to prevent severe neurodevelopmental impairment. Meanwhile, others adhere strictly to existing AAP guidelines that more conservatively recommend treatment starting at 36 weeks or later, citing concerns regarding potential side effects such as coagulopathy and hemodynamic instability inherent to lower gestational infants. This divergence often stems from local institutional policies, clinician experience, and parental expectations, resulting in inconsistent care standards, even within the same healthcare systems.

Confronted with this scenario, current American Academy of Pediatrics (AAP) guidance has evolved to explicitly recommend SDM processes between health providers and families in cases where therapeutic benefit is uncertain. SDM entails a collaborative dialogue where potential risks, benefits, and value-laden trade-offs are conveyed transparently to parents, empowering them to participate actively in deciding whether to pursue TH for their infant. This shift underscores a recognition that at 35 weeks’ gestation, the decision to initiate hypothermia therapy is inherently preference-sensitive and context-dependent. It is not merely a challenge of medical evidence but also one of individual parental values, beliefs, and tolerance for uncertainty.

The ethical frameworks driving this approach emphasize respect for parental autonomy while balancing the principles of beneficence and non-maleficence. Clinicians must navigate an intricate path whereby they neither impose aggressive intervention without clear benefit nor withhold potentially valuable therapy. This ethical tightrope necessitates enhanced communication skills and structured counseling strategies to distill complex scientific data into digestible, relatable information. Thus, training in neonatal neurocritical care not only covers technical competencies in treatment delivery but also prioritizes proficiency in empathetic, clear, and culturally sensitive dialogue.

Transparent communication forms the cornerstone for meaningful parental engagement. Discussions should encompass the limits of current knowledge, the ambiguity of prognostic outcomes, potential complications associated with hypothermia below 36 weeks, and alternative supportive measures. This approach reduces decisional conflict and fosters trust, allowing families to process information and weigh intervention options in alignment with their values. Neonatal teams benefit from utilizing decision aids, visual tools, and follow-up consultations to reinforce understanding and ensure that choices are informed and voluntary.

Furthermore, the rarity of this population segment and the ethical and logistical challenges in conducting large-scale randomized trials complicate knowledge generation. Thus, there is an emerging call to adopt pragmatic, parent-informed research methodologies that integrate real-world evidence and patient-centered outcomes. Such approaches might leverage registry data, adaptive trial designs, and innovative data sharing platforms to accelerate knowledge acquisition while respecting family preferences and clinical realities. Embedding parents as active collaborators in research development ensures that study protocols address relevant endpoints and ethical concerns.

Beyond evidence development, multidisciplinary collaboration is essential. Inclusion of neonatologists, neurologists, neurodevelopmental specialists, ethicists, and family advocates can facilitate holistic care models tailored to the unique risks and needs of 35-week infants undergoing TH consideration. Integration of neuroimaging, biomarker studies, and continuous neuro-monitoring technologies may further refine patient selection, optimizing individualized treatment decisions.

The ongoing clinical debate illuminates broader challenges in neonatology regarding the interface between imperfect evidence and complex medical decisions under uncertainty. It evokes a paradigm where science and ethics intertwine, demanding not only therapeutic innovation but also humane care delivery. Parents confronting unexpected neonatal complications deserve transparent partnerships, where their voices influence the trajectory of high-stakes interventions. As the evidence base evolves, so must clinical frameworks adapt to promote nuanced, compassionate, and evidence-informed treatments that respect the fragile beginnings of life at 35 weeks gestation.

In summary, therapeutic hypothermia at 35 weeks is a frontier marked by scientific ambiguity, ethical complexity, and variable clinical execution. The juxtaposition of randomized trial exclusions and observational study signals mandates a transition from command-and-control decision-making to participatory, family-centered approaches. Embedding SDM as routine practice aligns with contemporary care values and supports tailored decisions reflecting both evolving science and individual preferences. Future efforts should aim to harness collaborative research and interdisciplinary expertise to elucidate this treatment’s true potential while securing trust and clarity for families navigating the twilight zone of neonatal therapeutic uncertainty.

Subject of Research:

Article Title:

Article References:
El-Dib, M., Inder, T., Jalowsky, M. et al. Therapeutic hypothermia at 35 weeks’ gestation: navigating controversy between randomized evidence, real-world practice, and shared decision-making. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05228-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05228-5

Therapeutic hypothermia has been an established intervention in full-term infants with HIE, substantially improving neurological outcomes. However, the extension of this approach to preterm infants, particularly those below 36 weeks GA, remains contentious. The physiology of late preterm infants presents unique complexities; their brain maturation, metabolic rates, and susceptibility to injury differ significantly from those of full-term neonates. These physiological nuances necessitate meticulously designed trials to ascertain whether hypothermia can confer similar neuroprotection without introducing undue adverse effects.

The RCT conducted by Faix and colleagues specifically targeted the 33–35 weeks GA subgroup, a population often excluded from larger hypothermia trials yet representing a significant clinical challenge. The trial sought to evaluate both safety parameters and efficacy outcomes of whole body hypothermia in this cohort, employing stringent protocols to monitor neurological function, physiological responses, and long-term developmental trajectories. Despite the promising design and execution, the trial’s findings did not establish definitive efficacy or safety, underscoring the pressing need for further expansive research.

El-Dib’s critiques illuminate several methodological and interpretative challenges inherent in such clinical investigations. Issues raised include sample size limitations, potential confounders, and the scalability of trial findings to broader clinical practice. Faix et al. readily acknowledge these concerns, advocating for larger, multicenter trials with standardized methodologies to validate or refute their preliminary observations. This acknowledgment highlights the complexity of neonatal research, where ethical considerations and clinical urgencies intersect with statistical rigor and reproducibility.

A pivotal aspect of this ongoing dialogue is the delicate assessment of adverse effects potentially induced by hypothermia. In preterm infants, thermoregulatory mechanisms are inherently immature, and hypothermia may pose risks such as coagulopathy, electrolyte imbalances, or cardiac dysrhythmias. The trial meticulously tracked these parameters, reporting occurrences with precision, yet the small cohort size precludes broad generalization. Consequently, the safety profile remains indeterminate, demanding cautious optimism and rigorous surveillance in future explorations.

Neurological outcomes following hypoxic injury are multifaceted and evolve over time, necessitating longitudinal follow-up beyond immediate post-treatment phases. Faix and colleagues are transparent about this limitation, emphasizing that their study provides a snapshot rather than a definitive projection of long-term developmental impact. This temporal factor mandates a spectrum of research methodologies, including neuroimaging, electrophysiological studies, and comprehensive neurodevelopmental assessments extending into childhood.

The exchange provoked by El-Dib and the subsequent response by Faix et al. underscores a critical principle in translational neonatal research: the balance between innovation and evidence. It is tempting to extrapolate benefits observed in term infants to the preterm population, yet such decisions must be anchored in robust data to avoid unwarranted harm. This principle is particularly relevant in the context of HIE, where neurologic injury can have profound lifelong consequences, and therapeutic windows may be narrow.

Emerging biomarkers and advanced imaging techniques offer promising adjuncts to conventional clinical parameters, providing deeper insights into injury mechanisms and treatment responses. Incorporating such tools into future hypothermia trials may enhance patient stratification, risk assessment, and individualized therapy. This multi-modal approach aligns with precision medicine paradigms increasingly adopted across neonatology and pediatrics.

The discourse also opens avenues for exploring adjunct therapies alongside hypothermia, potentially synergizing neuroprotective effects. Pharmacologic agents targeting oxidative stress, inflammation, or excitotoxic pathways are under investigation, raising possibilities for combination therapies tailored to gestational age and injury severity. Integrating such modalities necessitates a foundational understanding of hypothermia’s role and limitations in the preterm brain’s milieu.

Clinical implementation of whole body hypothermia in the late preterm population must proceed cautiously, with multidisciplinary teams closely monitoring treatment response and complications. Standardized protocols, inclusive of inclusion-exclusion criteria, temperature targets, and monitoring guidelines, are vital to maintaining patient safety. Furthermore, caregivers and families require transparent communication regarding benefits, uncertainties, and potential risks to facilitate informed decision-making.

Pharmacokinetic and pharmacodynamic variations in preterm infants also merit consideration when applying therapeutic hypothermia. Hypothermia can alter drug metabolism and organ function, potentially affecting concomitant treatments. Tailoring medication regimens alongside hypothermia demands careful attention to dosing, timing, and adverse effect profiles, reinforcing the necessity for comprehensive clinical protocols and vigilant monitoring.

The discussion extends beyond immediate clinical outcomes to health economics and resource allocation. Hypothermia therapy involves specialized equipment, trained personnel, and hospitalization in neonatal intensive care units. Assessing cost-effectiveness relative to clinical benefit, particularly in populations with uncertain efficacy, is essential to inform health policy and optimize resource utilization without compromising care quality.

International collaboration presents an optimal framework for advancing knowledge in this arena. Pooling data through multicenter registries and harmonizing trial designs can enhance statistical power and generalizability. Such alliances also foster knowledge exchange and establish consensus guidelines, accelerating the translation of research findings into standardized clinical practice.

As neonatal care continues to evolve, so does the ethical landscape surrounding experimental therapies in vulnerable populations. The imperative to alleviate suffering and prevent disability must be balanced against the potential for harm from unproven interventions. Transparent reporting, ongoing ethical scrutiny, and engagement with families underpin responsible clinical research and practice in this sensitive domain.

Ultimately, the exchange between El-Dib and Faix et al. epitomizes scientific discourse’s vital role in refining neonatal therapeutic strategies. Through robust debate and critical appraisal, the field can move closer to establishing safe, effective interventions that improve outcomes for late preterm infants afflicted with hypoxic-ischemic insults. The current RCT provides a foundational platform, yet it is clear that further rigorous investigation is indispensable.

In this complex and rapidly advancing field, clinicians and researchers must remain vigilant, agile, and collaborative. The pursuit of evidence-backed treatments for HIE in late preterm infants holds the promise of transforming vulnerable lives. However, this promise can only be fulfilled by steadfast commitment to methodical, ethical, and transparent research endeavors that honor the trust placed in the caregivers of our youngest patients.

Subject of Research: Therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants (33–35 weeks gestational age).

Article Title: Reply to: Benefits and risks of therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants.

Article References:
Faix, R.G., Laptook, A.R., Shankaran, S. et al. Reply to: Benefits and risks of therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04675-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04675-w